Jacob W Brubaker, MD
Ophthalmology · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 19 years
- Graduated 2007
Offices
1 location · Sacramento Eye Consultants A Med Corp · 10 clinicians in this group
Hospitals listed: Mercy General Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Brubaker’s office at (916) 649-1515 to ask if they take your plan before you enroll.
California Medical Board record
Licence A124655 · Current
Licensed to practise in California · since 2013 · expires 2028-04-30 · Mcgill University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mercy General HospitalSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.43 (1.15 to 1.7), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 2.85 (2.2 to 3.51) · 4,531 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.124, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.18, Oct 2024 – Sep 2025
See every measure and the patient survey for Mercy General Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.43 (1.15 to 1.7) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 2.85 (2.2 to 3.51) · 4,531 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.124 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.18 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.82 (0 to 1.78) · 1,035 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.19 (116.89 to 215.48) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.2 · 431 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.8 · 348 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 242 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,346 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,509 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.06 to 0.45) · 6,091 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (1.01 to 4.84) · 1,995 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.42 (0.01 to 2.83) · 863 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.86 (0.49 to 3.22) · 1,834 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.67 (1.97 to 11.37) · 927 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.8 (0 to 5.97) · 914 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.06) · 331 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 171 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.457 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.426 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.306 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 902 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 642 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.6 · 513 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 23.5 · 445 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.5 · 229 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 349 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 295 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.4 · 175 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.3 to 16.4) · 405 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 516 cases | No different | Jan 2024 – Dec 2024 |
What patients said (477 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$517,984
Medicare paid this office $517,984 for 1,294 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of cataract with insertion of prosthetic lens | 128 | $77,368 | $393 |
| Established patient problem focused exam of visual system | 542 | $46,046 | $66 |
| Exam of visual field with extended testing | 808 | $40,851 | $49 |
| Return visit (30+ min) | 321 | $33,587 | $90 |
| Extracapsular removal of cataract with insertion of artificial lens and insertion of drainage device in front chamber of eye | 40 | $33,161 | $553 |
See all 26 services
| Removal of cataract with insertion of prosthetic lens | 128 | $77,368 | $393 |
| Established patient problem focused exam of visual system | 542 | $46,046 | $66 |
| Exam of visual field with extended testing | 808 | $40,851 | $49 |
| Return visit (30+ min) | 321 | $33,587 | $90 |
| Extracapsular removal of cataract with insertion of artificial lens and insertion of drainage device in front chamber of eye | 40 | $33,161 | $553 |
| Established patient complete exam of visual system | 359 | $31,026 | $84 |
| New patient visit (45+ min) | 250 | $29,763 | $119 |
| Incision to improve eye fluid flow | 31 | $24,610 | $684 |
| Insertion of eye fluid drainage device | 25 | $24,132 | $862 |
| Imaging of optic nerve | 891 | $23,106 | $25 |
| Telephone medical discussion with physician, 11-20 minutes | 314 | $21,410 | $66 |
| Creation of shunt to improve eye fluid flow using tissue graft | 21 | $20,708 | $941 |
| Laser repair to improve eye fluid flow | 76 | $17,942 | $236 |
| Removal of recurring cataract in lens capsule using a laser | 53 | $16,019 | $297 |
| Photography of the retina | 551 | $14,329 | $26 |
| Destruction of lens tissue using laser | 34 | $12,118 | $337 |
| Measurement of corneal curvature and depth of eye | 261 | $10,849 | $35 |
| New patient complete exam of visual system | 103 | $10,606 | $103 |
| Exam of the internal drainage system of eye | 171 | $3,573 | $21 |
| Ultrasound scan of cornea to determine thickness | 232 | $1,844 | $8 |
| Imaging of retina | 54 | $1,568 | $29 |
| Exam of visual field with intermediate testing | 45 | $1,476 | $33 |
| Short return visit (20+ min) | 15 | $1,226 | $77 |
| Short return visit | 11 | $529 | $48 |
| Ct scan of cornea | 18 | $484 | $27 |
| Insertion of drug delivery implant into tear duct of eye | 16 | $321 | $13 |
Procedures Medicare counted
| Cataract surgery | 393 | More than 93% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of cataract with insertion of prosthetic lens | 128 | 132 | 245 | 217 | 209 | 197 |
| Laser repair to improve eye fluid flow | 34 | 32 | 28 | 50 | 69 | 76 |
| Incision to improve eye fluid flow | 45 | 32 | 54 | 72 | 39 | 36 |
| Creation of shunt to improve eye fluid flow using tissue graft | 84 | 42 | 59 | 36 | 29 | 22 |
| Insertion of drug delivery implant into tear duct of eye | – | – | – | 139 | 59 | 24 |
| Removal of recurring cataract in lens capsule using a laser | 43 | 21 | 30 | 36 | 33 | 54 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,294 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 20% · Women 59% · Also on Medicaid 17% · Health risk score 1.09. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 68% · Diabetes 24% · Chronic kidney disease 24% · Coronary heart disease 20% · Atrial fibrillation 16% · Cancer 14% · Depression 14% · COPD 12% · Heart failure 11% · Stroke 7% · Dementia 5%.
The office billed $2,090,156, Medicare allowed $712,331 and paid $517,984; for 5,865 services of 45 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,294 | 5,865 | 77 | 1.09 | $2,090,156 | $517,984 |
| 2023 | 1,254 | 5,894 | 77 | 1.13 | $2,056,167 | $509,966 |
| 2022 | 1,354 | 6,000 | 77 | 1.14 | $2,251,922 | $534,835 |
| 2021 | 1,343 | 6,160 | 76 | 1.07 | $2,272,081 | $565,627 |
| 2020 | 1,181 | 5,003 | 77 | 1.08 | $1,633,310 | $435,379 |
| 2019 | 1,267 | 5,860 | 76 | 1.12 | $1,622,865 | $548,648 |
| 2018 | 1,120 | 4,795 | 76 | 1.16 | $935,285 | $414,917 |
| 2017 | 997 | 4,566 | 76 | 1.19 | $867,511 | $392,069 |
| 2016 | 983 | 4,219 | 76 | 1.27 | $867,910 | $409,486 |
| 2015 | 925 | 3,717 | 76 | 1.18 | $782,380 | $368,794 |
| 2014 | 1,148 | 3,723 | 76 | 0.99 | $890,745 | $413,372 |
| 2013 | 424 | 996 | 75 | 1.01 | $161,861 | $84,641 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Removal of cataract with insertion of prosthetic lens | 134 | $81,002 | $388 |
| Established patient problem focused exam of visual system | 703 | $64,031 | $66 |
| Established patient complete exam of visual system | 452 | $42,588 | $89 |
| Exam of visual field with extended testing | 649 | $32,359 | $49 |
| New patient complete exam of visual system | 287 | $30,187 | $105 |
| Incision to improve eye fluid flow | 29 | $27,368 | $702 |
| Creation of shunt to improve eye fluid flow using tissue graft | 27 | $26,384 | $910 |
| Extracapsular removal of cataract with insertion of artificial lens and insertion of drainage device in front chamber of eye | 33 | $25,479 | $554 |
| Insertion of eye fluid drainage device | 24 | $23,550 | $872 |
| Imaging of optic nerve | 870 | $23,039 | $26 |
| Telephone medical discussion with physician, 11-20 minutes | 321 | $21,904 | $68 |
| Laser repair to improve eye fluid flow | 69 | $16,575 | $240 |
| Photography of the retina | 549 | $14,791 | $27 |
| Return visit (30+ min) | 90 | $10,073 | $105 |
| Removal of recurring cataract in lens capsule using a laser | 32 | $9,733 | $295 |
| Measurement of corneal curvature and depth of eye | 208 | $8,980 | $34 |
| Destruction of lens tissue using laser | 24 | $8,251 | $330 |
| Exam of visual field with intermediate testing | 211 | $8,106 | $38 |
| New patient visit (45+ min) | 56 | $7,356 | $131 |
| Exam of the internal drainage system of eye | 180 | $3,970 | $22 |
| Ultrasound scan of cornea to determine thickness | 246 | $2,039 | $8 |
| Imaging of retina | 57 | $1,860 | $32 |
| Insertion of drug delivery implant into tear duct of eye | 46 | $812 | $14 |
| Ct scan of cornea | 15 | $405 | $27 |
2022: 22 services
| Removal of cataract with insertion of prosthetic lens | 142 | $81,506 | $376 |
| Established patient problem focused exam of visual system | 778 | $77,848 | $65 |
| Established patient complete exam of visual system | 503 | $47,686 | $89 |
| Incision to improve eye fluid flow | 48 | $46,209 | $642 |
| New patient complete exam of visual system | 333 | $35,581 | $107 |
| Creation of shunt to improve eye fluid flow using tissue graft | 33 | $34,376 | $955 |
| Exam of visual field with extended testing | 643 | $29,738 | $46 |
| Imaging of optic nerve | 840 | $22,151 | $26 |
| Extracapsular removal of cataract with insertion of artificial lens and insertion of drainage device in front chamber of eye | 34 | $20,666 | $459 |
| Telephone medical discussion with physician, 11-20 minutes | 306 | $19,541 | $63 |
| Insertion of eye fluid drainage device | 16 | $15,568 | $865 |
| Photography of the retina | 510 | $13,420 | $26 |
| Laser repair to improve eye fluid flow | 50 | $12,426 | $249 |
| Removal of recurring cataract in lens capsule using a laser | 35 | $10,727 | $298 |
| Destruction of lens tissue using laser | 32 | $10,636 | $332 |
| Measurement of corneal curvature and depth of eye | 203 | $8,914 | $34 |
| Complex removal of cataract with insertion of prosthetic lens | 15 | $7,643 | $510 |
| Exam of visual field with intermediate testing | 209 | $7,605 | $36 |
| Exam of the internal drainage system of eye | 136 | $2,974 | $22 |
| Insertion of drug delivery implant into tear duct of eye | 98 | $1,892 | $14 |
| Ultrasound scan of cornea to determine thickness | 198 | $1,666 | $8 |
| Imaging of retina | 43 | $1,166 | $26 |
2021: 23 services
| Removal of cataract with insertion of prosthetic lens | 163 | $94,943 | $388 |
| Established patient problem focused exam of visual system | 737 | $77,193 | $67 |
| Creation of shunt to improve eye fluid flow using tissue graft | 55 | $56,257 | $954 |
| Established patient complete exam of visual system | 551 | $55,990 | $91 |
| New patient complete exam of visual system | 359 | $40,840 | $114 |
| Incision to improve eye fluid flow | 41 | $36,462 | $675 |
| Exam of visual field with extended testing | 642 | $30,572 | $46 |
| Imaging of optic nerve | 860 | $22,833 | $26 |
| Insertion of eye fluid drainage device | 23 | $21,556 | $862 |
| Internal insertion of eye fluid drainage device | 40 | $16,051 | $277 |
| Telephone medical discussion with physician, 11-20 minutes | 227 | $14,334 | $63 |
| Photography of the retina | 531 | $14,151 | $26 |
| Measurement of corneal curvature and depth of eye | 215 | $10,713 | $38 |
| Exam of visual field with intermediate testing | 246 | $9,586 | $39 |
| Removal of recurring cataract in lens capsule using a laser | 30 | $9,018 | $301 |
| Destruction of lens tissue using laser | 25 | $8,393 | $311 |
| Laser repair to improve eye fluid flow | 28 | $5,895 | $211 |
| Exam of the internal drainage system of eye | 143 | $3,295 | $23 |
| Imaging of retina | 88 | $2,777 | $31 |
| Ultrasound scan of cornea to determine thickness | 197 | $1,750 | $9 |
| Insertion of drug delivery implant into tear ducts | 49 | $1,593 | $23 |
| Ct scan of cornea | 56 | $1,530 | $27 |
| Short return visit (20+ min) | 20 | $364 | $18 |
2020: 22 services
| Established patient problem focused exam of visual system | 673 | $63,119 | $60 |
| Removal of cataract with insertion of prosthetic lens | 98 | $51,574 | $391 |
| Creation of shunt to improve eye fluid flow using tissue graft | 39 | $40,386 | $962 |
| Established patient complete exam of visual system | 349 | $33,184 | $90 |
| New patient complete exam of visual system | 319 | $33,150 | $104 |
| Insertion of eye fluid drainage device | 28 | $29,118 | $882 |
| Exam of visual field with extended testing | 498 | $23,916 | $47 |
| Incision to improve eye fluid flow | 27 | $20,745 | $648 |
| Imaging of optic nerve | 735 | $19,718 | $26 |
| Photography of the retina | 467 | $15,046 | $32 |
| Exam of visual field with intermediate testing | 291 | $11,329 | $39 |
| Telephone medical discussion with physician, 11-20 minutes | 171 | $9,579 | $56 |
| Internal insertion of eye fluid drainage device | 29 | $8,751 | $224 |
| Insertion of initial aqueous fluid drainage device into eye | 16 | $8,153 | $480 |
| Destruction of lens tissue using laser | 21 | $7,241 | $315 |
| Laser repair to improve eye fluid flow | 31 | $7,124 | $223 |
| Short return visit (20+ min) | 112 | $6,916 | $61 |
| Removal of recurring cataract in lens capsule using a laser | 21 | $6,308 | $300 |
| Measurement of corneal curvature and depth of eye | 92 | $4,765 | $45 |
| Exam of the internal drainage system of eye | 138 | $3,129 | $23 |
| Ultrasound scan of cornea to determine thickness | 223 | $2,050 | $9 |
| Imaging of retina | 23 | $776 | $34 |
2019: 24 services
| Established patient problem focused exam of visual system | 888 | $119,039 | $66 |
| Creation of shunt to improve eye fluid flow using tissue graft | 78 | $80,839 | $962 |
| Removal of cataract with insertion of prosthetic lens | 106 | $54,956 | $429 |
| New patient complete exam of visual system | 391 | $43,432 | $111 |
| Established patient complete exam of visual system | 320 | $29,753 | $91 |
| Exam of visual field with extended testing | 515 | $26,510 | $50 |
| Incision to improve eye fluid flow | 40 | $26,004 | $578 |
| Imaging of optic nerve | 790 | $21,917 | $27 |
| Insertion of eye fluid drainage device | 24 | $21,706 | $868 |
| Photography of the retina | 403 | $14,835 | $36 |
| Exam of visual field with intermediate testing | 346 | $13,495 | $39 |
| Removal of recurring cataract in lens capsule using a laser | 42 | $12,649 | $294 |
| Internal insertion of eye fluid drainage device | 43 | $8,388 | $175 |
| Measurement of corneal curvature and depth of eye | 135 | $7,835 | $55 |
| Insertion of initial aqueous fluid drainage device into eye | 30 | $7,397 | $218 |
| Complex removal of cataract with insertion of prosthetic lens | 11 | $6,911 | $628 |
| Revision or repair of operative wound of eye | 11 | $6,848 | $623 |
| Laser repair to improve eye fluid flow | 31 | $6,647 | $196 |
| Destruction of lens tissue using laser | 16 | $5,661 | $333 |
| Exam of the internal drainage system of eye | 202 | $4,716 | $23 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 14 | $4,555 | $285 |
| Ultrasound scan of cornea to determine thickness | 287 | $2,814 | $10 |
| Imaging of retina | 52 | $1,691 | $30 |
| New patient problem focused exam of visual system | 12 | $790 | $66 |
2018: 19 services
| Established patient problem focused exam of visual system | 730 | $95,466 | $65 |
| Removal of cataract with insertion of prosthetic lens | 93 | $56,598 | $468 |
| Creation of shunt to improve eye fluid flow using tissue graft | 49 | $49,135 | $945 |
| New patient complete exam of visual system | 324 | $37,322 | $115 |
| Established patient complete exam of visual system | 292 | $27,982 | $94 |
| Exam of visual field with extended testing | 500 | $24,699 | $49 |
| Imaging of optic nerve | 656 | $18,531 | $28 |
| Photography of the retina | 320 | $13,943 | $42 |
| Incision to improve eye fluid flow | 21 | $13,725 | $597 |
| Removal of recurring cataract in lens capsule using a laser | 31 | $9,239 | $280 |
| Insertion of initial aqueous fluid drainage device into eye | 32 | $7,945 | $215 |
| Measurement of corneal curvature and depth of eye | 115 | $7,344 | $53 |
| Exam of visual field with intermediate testing | 187 | $6,844 | $37 |
| Internal insertion of eye fluid drainage device | 23 | $5,003 | $173 |
| Destruction of lens tissue using laser | 14 | $4,865 | $324 |
| Exam of the internal drainage system of eye | 179 | $4,097 | $22 |
| Laser repair to improve eye fluid flow | 19 | $3,900 | $186 |
| Ultrasound scan of cornea to determine thickness | 232 | $2,753 | $12 |
| Imaging of retina | 51 | $1,653 | $32 |
2017: 21 services
| Established patient problem focused exam of visual system | 681 | $77,805 | $62 |
| Removal of cataract with insertion of prosthetic lens | 106 | $67,301 | $458 |
| New patient complete exam of visual system | 311 | $35,236 | $113 |
| Incision to improve eye fluid flow | 39 | $27,503 | $598 |
| Creation of shunt to improve eye fluid flow using tissue graft | 25 | $24,053 | $925 |
| Imaging of optic nerve | 597 | $16,446 | $27 |
| Internal insertion of eye fluid drainage device | 21 | $15,675 | $560 |
| Established patient complete exam of visual system | 161 | $15,159 | $94 |
| Photography of the retina | 301 | $14,561 | $48 |
| Exam of visual field with extended testing | 309 | $14,415 | $45 |
| Exam of visual field with intermediate testing | 375 | $13,248 | $35 |
| Measurement of corneal curvature and depth of eye | 132 | $9,826 | $36 |
| Destruction of lens tissue using laser | 21 | $7,057 | $321 |
| Laser repair to improve eye fluid flow | 30 | $6,179 | $187 |
| Removal of recurring cataract in lens capsule using a laser | 21 | $5,781 | $275 |
| Exam of the internal drainage system of eye | 208 | $4,513 | $21 |
| Ultrasound scan of cornea to determine thickness | 258 | $2,930 | $11 |
| Insertion of drainage device and creation of fluid reservoir in front chamber of eye | 13 | $2,575 | $151 |
| Imaging of retina | 32 | $1,064 | $31 |
| Short return visit (20+ min) | 12 | $722 | $56 |
| Short return visit | 14 | $674 | $35 |
2016: 22 services
| Removal of cataract with insertion of prosthetic lens | 112 | $74,368 | $471 |
| Established patient problem focused exam of visual system | 660 | $70,873 | $62 |
| Creation of shunt to improve eye fluid flow using tissue graft | 42 | $41,167 | $936 |
| New patient complete exam of visual system | 322 | $35,819 | $111 |
| Internal insertion of eye fluid drainage device | 29 | $30,710 | $808 |
| Imaging of optic nerve | 491 | $15,767 | $31 |
| Exam of visual field with intermediate testing | 424 | $14,415 | $34 |
| Photography of the retina | 221 | $13,397 | $59 |
| Creation of eye fluid drainage tract for treatment of glaucoma with previous scarring | 11 | $12,275 | $1,023 |
| Exam of visual field with extended testing | 256 | $12,071 | $46 |
| Measurement of corneal curvature and depth of eye | 138 | $9,948 | $35 |
| Dilation of fluid outflow drainage within eye with insertion of device to maintain open channel | 11 | $9,856 | $821 |
| Established patient complete exam of visual system | 95 | $9,081 | $95 |
| Removal of recurring cataract in lens capsule using a laser | 23 | $6,662 | $278 |
| Laser repair to improve eye fluid flow | 24 | $5,616 | $208 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 12 | $3,882 | $259 |
| Exam of the internal drainage system of eye | 184 | $3,868 | $21 |
| Destruction of lens tissue using laser | 12 | $3,780 | $315 |
| Imaging of retina | 72 | $2,453 | $31 |
| Ultrasound scan of cornea to determine thickness | 216 | $2,404 | $11 |
| Short return visit | 21 | $753 | $33 |
| Ct scan of cornea | 12 | $286 | $24 |
2015: 21 services
| Removal of cataract with insertion of prosthetic lens | 96 | $67,950 | $482 |
| Established patient problem focused exam of visual system | 583 | $63,430 | $63 |
| Creation of shunt to improve eye fluid flow using tissue graft | 34 | $35,702 | $940 |
| New patient complete exam of visual system | 310 | $33,188 | $107 |
| Internal insertion of eye fluid drainage device | 24 | $25,779 | $806 |
| Dilation of fluid outflow drainage within eye with insertion of device to maintain open channel | 24 | $21,860 | $810 |
| Imaging of optic nerve | 497 | $16,651 | $32 |
| Exam of visual field with intermediate testing | 375 | $13,926 | $37 |
| Exam of visual field with extended testing | 290 | $12,535 | $43 |
| Insertion of eye fluid drainage device | 12 | $11,112 | $855 |
| Measurement of corneal curvature and depth of eye | 131 | $9,515 | $36 |
| Destruction of lens tissue using laser | 25 | $9,126 | $326 |
| Removal of recurring cataract in lens capsule using a laser | 24 | $6,363 | $265 |
| Established patient complete exam of visual system | 65 | $5,623 | $84 |
| Laser repair to improve eye fluid flow | 13 | $4,350 | $290 |
| Photography of the retina | 64 | $4,185 | $63 |
| Exam of the internal drainage system of eye | 155 | $3,518 | $22 |
| Ultrasound scan of cornea to determine thickness | 198 | $2,309 | $12 |
| Imaging of retina | 46 | $1,703 | $34 |
| Short return visit | 16 | $422 | $26 |
| Ct scan of cornea | 13 | $320 | $25 |
2014: 19 services
| Removal of cataract with insertion of prosthetic lens | 121 | $81,309 | $478 |
| Creation of shunt to improve eye fluid flow using tissue graft | 39 | $44,531 | $947 |
| Established patient problem focused exam of visual system | 401 | $41,503 | $66 |
| Established patient complete exam of visual system | 332 | $33,213 | $89 |
| New patient complete exam of visual system | 261 | $27,972 | $107 |
| Exam of visual field with extended testing | 542 | $25,210 | $45 |
| Dilation of fluid outflow drainage within eye with insertion of device to maintain open channel | 22 | $21,924 | $877 |
| Internal insertion of eye fluid drainage device | 23 | $20,990 | $807 |
| Repair of defect of sclera with graft | 40 | $17,671 | $368 |
| Imaging of optic nerve | 528 | $17,447 | $32 |
| Exam of visual field with intermediate testing | 342 | $13,451 | $39 |
| Removal of recurring cataract in lens capsule using a laser | 37 | $10,924 | $280 |
| Measurement of corneal curvature and depth of eye | 104 | $7,749 | $37 |
| Destruction of lens tissue using laser | 21 | $6,789 | $323 |
| Laser repair to improve eye fluid flow | 16 | $5,854 | $308 |
| Exam of the internal drainage system of eye | 109 | $2,437 | $22 |
| Imaging of retina | 51 | $1,942 | $36 |
| Ultrasound scan of cornea to determine thickness | 149 | $1,728 | $12 |
| Short return visit (20+ min) | 17 | $916 | $51 |
2013: 11 services
| New patient complete exam of visual system | 91 | $10,951 | $120 |
| Established patient problem focused exam of visual system | 126 | $10,609 | $69 |
| Exam of visual field with extended testing | 168 | $9,080 | $54 |
| Established patient complete exam of visual system | 87 | $9,008 | $99 |
| Removal of cataract with insertion of prosthetic lens | 11 | $5,013 | $418 |
| Imaging of optic nerve | 138 | $4,754 | $34 |
| Exam of visual field with intermediate testing | 95 | $3,829 | $40 |
| Measurement of corneal curvature and depth of eye | 19 | $1,420 | $37 |
| Exam of the internal drainage system of eye | 46 | $1,075 | $22 |
| Imaging of retina | 17 | $610 | $36 |
| Ultrasound scan of cornea to determine thickness | 47 | $542 | $12 |
Medicaid work
$3,649 in 2024
Medicaid paid $3,649 for 423 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 116 | $1,345 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 118 | $889 |
| Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation | 37 | $633 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 114 | $490 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 13 | $236 |
| Return visit (30+ min) | 13 | $34 |
| Ophthalmic ultrasound, diagnostic; corneal pachymetry, unilateral or bilateral (determination of corneal thickness) | 12 | $22 |
| 2024 | 423 | 7 | 22 | $3,649 |
| 2023 | 512 | 8 | 24 | $7,878 |
| 2022 | 296 | 5 | 23 | $1,940 |
| 2021 | 240 | 4 | 20 | $2,054 |
| 2020 | 109 | 2 | 30 | $1,852 |
| 2019 | 58 | 1 | 16 | $794 |
| 2018 | 90 | 1 | 19 | $1,016 |
See the largest Medicaid services in earlier years
2023
| XCAPSL CTRC RMVL INSJ IO LENS PROSTH W/O ECP | 26 | $2,226 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 180 | $2,153 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 169 | $1,558 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 15 | $740 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 29 | $419 |
| Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation | 53 | $365 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 25 | $254 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $163 |
2022
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 185 | $896 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 36 | $453 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 41 | $382 |
| Unclassified drugs | 22 | $150 |
| INTERMEDIATE VISUAL FIELD XM | 12 | $61 |
2021
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 112 | $1,084 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 86 | $536 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 30 | $413 |
| INTERMEDIATE VISUAL FIELD XM | 12 | $20 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 82 | $1,705 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 27 | $146 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 58 | $794 |
2018
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 90 | $1,016 |
Drugs they prescribed that Part D paid
$945,561
Pharmacies billed $945,561 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
4,737 generic and 3,202 brand-name prescriptions · $945,561 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lumigan | 443 | $234,175 | $529 |
| Rocklatan | 180 | $105,498 | $586 |
| Rhopressa | 178 | $88,390 | $497 |
| Simbrinza | 265 | $65,529 | $247 |
| Brimonidine Tartrate-Timolol | 206 | $44,479 | $216 |
See all 35 drugs
| Lumigan | 443 | $234,175 | $529 |
| Rocklatan | 180 | $105,498 | $586 |
| Rhopressa | 178 | $88,390 | $497 |
| Simbrinza | 265 | $65,529 | $247 |
| Brimonidine Tartrate-Timolol | 206 | $44,479 | $216 |
| Vyzulta | 86 | $39,533 | $460 |
| Combigan | 99 | $38,775 | $392 |
| Alphagan P | 72 | $28,423 | $395 |
| Latanoprost | 1,865 | $28,029 | $15 |
| Brimonidine | 351 | $27,284 | $78 |
| Travoprost | 141 | $26,980 | $191 |
| Dorzolamide-Timolol | 1,255 | $22,693 | $18 |
| Prednisolone Acetate | 337 | $16,396 | $49 |
| Iyuzeh | 34 | $15,211 | $447 |
| Timolol Maleate | 28 | $14,809 | $529 |
| Loteprednol Etabonate | 103 | $13,558 | $132 |
| Dorzolamide-Timolol | 73 | $12,490 | $171 |
| Brinzolamide | 82 | $12,291 | $150 |
| Ketorolac Tromethamine | 483 | $10,510 | $22 |
| Tafluprost | 64 | $10,020 | $157 |
| Zioptan | 22 | $9,408 | $428 |
| Travatan Z | 22 | $9,128 | $415 |
| Azopt | 11 | $8,273 | $752 |
| Timolol Maleate | 622 | $7,763 | $12 |
| Restasis Multidose | 11 | $7,038 | $640 |
| Ofloxacin | 407 | $4,077 | $10 |
| Difluprednate | 42 | $3,993 | $95 |
| Dorzolamide | 180 | $3,942 | $22 |
| Bimatoprost | 19 | $2,123 | $112 |
| Atropine Sulfate | 64 | $1,499 | $23 |
| Fluorometholone | 14 | $1,350 | $96 |
| Pilocarpine | 11 | $936 | $85 |
| Neomycin-Polymyxin-Dexameth | 34 | $384 | $11 |
| Erythromycin | 16 | $170 | $11 |
| Polymyxin B Sul-Trimethoprim | 12 | $79 | $7 |
Year by year
| 2024 | 7,939 | 1,333 | None | 40% | $945,561 |
| 2023 | 7,426 | 1,237 | 0% (0) | 41% | $1,004,161 |
| 2022 | 7,357 | 1,268 | None | 42% | $954,895 |
| 2021 | 7,190 | 1,178 | 0% (0) | 48% | $939,958 |
| 2020 | 6,302 | 1,077 | 0% (0) | 49% | $940,837 |
| 2019 | 5,928 | 1,047 | None | 51% | $876,024 |
| 2018 | 4,904 | 928 | 0% (0) | 53% | $635,788 |
| 2017 | 3,970 | 844 | 0% (0) | 45% | $432,139 |
| 2016 | 3,967 | 777 | None | 47% | $393,939 |
| 2015 | 2,958 | 634 | 0% (0) | 51% | $270,909 |
| 2014 | 1,730 | 429 | 1% (20) | 48% | $134,220 |
| 2013 | 396 | 195 | 24% (95) | None | $17,550 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Lumigan | 400 | $213,655 | $534 |
| Rocklatan | 167 | $99,319 | $595 |
| Rhopressa | 152 | $84,415 | $555 |
| Combigan | 126 | $62,629 | $497 |
| Simbrinza | 208 | $62,517 | $301 |
| Brimonidine Tartrate-Timolol | 188 | $58,985 | $314 |
| Latanoprost | 1,758 | $51,604 | $29 |
| Alphagan P | 114 | $40,636 | $356 |
| Dorzolamide-Timolol | 1,208 | $40,373 | $33 |
| Vyzulta | 82 | $36,110 | $440 |
| Travoprost | 152 | $32,724 | $215 |
| Brinzolamide | 63 | $19,586 | $311 |
| Brimonidine | 367 | $18,783 | $51 |
| Prednisolone Acetate | 299 | $16,966 | $57 |
| Loteprednol Etabonate | 89 | $15,335 | $172 |
| Timolol Maleate | 598 | $14,771 | $25 |
| Dorzolamide-Timolol | 55 | $11,674 | $212 |
| Tafluprost | 57 | $11,443 | $201 |
| Ketorolac Tromethamine | 389 | $9,726 | $25 |
| Timolol Maleate | 23 | $9,675 | $421 |
| Zioptan | 24 | $9,424 | $393 |
| Azopt | 17 | $9,267 | $545 |
| Travatan Z | 19 | $8,913 | $469 |
| Dorzolamide | 210 | $7,685 | $37 |
| Difluprednate | 44 | $5,299 | $120 |
| Ofloxacin | 327 | $4,749 | $15 |
| Atropine Sulfate | 59 | $1,933 | $33 |
| Fluorometholone | 16 | $1,532 | $96 |
| Moxifloxacin | 21 | $697 | $33 |
| Neomycin-Polymyxin-Dexameth | 40 | $532 | $13 |
| Erythromycin | 19 | $217 | $11 |
| Carteolol | 11 | $202 | $18 |
2022: 31 drugs
| Lumigan | 422 | $211,281 | $501 |
| Rocklatan | 155 | $80,218 | $518 |
| Rhopressa | 152 | $79,524 | $523 |
| Combigan | 158 | $68,693 | $435 |
| Simbrinza | 215 | $56,274 | $262 |
| Latanoprost | 1,801 | $55,773 | $31 |
| Alphagan P | 135 | $49,288 | $365 |
| Dorzolamide-Timolol | 1,103 | $38,123 | $35 |
| Brimonidine Tartrate-Timolol | 133 | $36,671 | $276 |
| Travoprost | 149 | $35,683 | $239 |
| Vyzulta | 73 | $30,454 | $417 |
| Prednisolone Acetate | 346 | $20,647 | $60 |
| Zioptan | 58 | $19,465 | $336 |
| Brimonidine | 383 | $17,293 | $45 |
| Timolol Maleate | 591 | $15,549 | $26 |
| Brinzolamide | 42 | $14,328 | $341 |
| Loteprednol Etabonate | 76 | $12,595 | $166 |
| Travatan Z | 26 | $11,611 | $447 |
| Azopt | 26 | $11,543 | $444 |
| Prolensa | 23 | $8,808 | $383 |
| Timolol Maleate | 18 | $7,729 | $429 |
| Ketorolac Tromethamine | 339 | $7,606 | $22 |
| Dorzolamide-Timolol | 39 | $7,479 | $192 |
| Dorzolamide | 192 | $6,567 | $34 |
| Ofloxacin | 370 | $4,508 | $12 |
| Difluprednate | 20 | $3,336 | $167 |
| Atropine Sulfate | 74 | $2,187 | $30 |
| Acetazolamide | 14 | $1,770 | $126 |
| Neomycin-Polymyxin-Dexameth | 63 | $1,005 | $16 |
| Fluorometholone | 11 | $979 | $89 |
| Pilocarpine | 11 | $918 | $83 |
2021: 31 drugs
| Lumigan | 399 | $190,454 | $477 |
| Combigan | 309 | $126,370 | $409 |
| Rocklatan | 165 | $71,421 | $433 |
| Rhopressa | 116 | $60,887 | $525 |
| Latanoprost | 1,866 | $54,902 | $29 |
| Alphagan P | 157 | $54,115 | $345 |
| Simbrinza | 185 | $53,097 | $287 |
| Dorzolamide-Timolol | 1,079 | $42,306 | $39 |
| Travoprost | 123 | $35,456 | $288 |
| Azopt | 49 | $21,658 | $442 |
| Travatan Z | 52 | $21,456 | $413 |
| Prednisolone Acetate | 338 | $21,335 | $63 |
| Vyzulta | 49 | $18,870 | $385 |
| Zioptan | 46 | $17,411 | $378 |
| Restasis | 16 | $16,446 | $1,028 |
| Brimonidine | 296 | $16,206 | $55 |
| Loteprednol Etabonate | 75 | $12,848 | $171 |
| Brinzolamide | 26 | $10,812 | $416 |
| Dorzolamide-Timolol | 54 | $10,788 | $200 |
| Timolol Maleate | 525 | $10,442 | $20 |
| Durezol | 42 | $9,266 | $221 |
| Ketorolac Tromethamine | 295 | $7,832 | $27 |
| Dorzolamide | 154 | $6,100 | $40 |
| Timolol Maleate | 13 | $5,850 | $450 |
| Ofloxacin | 376 | $5,093 | $14 |
| Atropine Sulfate | 122 | $5,071 | $42 |
| Betimol | 14 | $2,098 | $150 |
| Neomycin-Polymyxin-Dexameth | 97 | $1,474 | $15 |
| Pilocarpine | 13 | $1,369 | $105 |
| Erythromycin | 16 | $178 | $11 |
| Polymyxin B Sul-Trimethoprim | 17 | $120 | $7 |
2020: 33 drugs
| Lumigan | 402 | $193,118 | $480 |
| Combigan | 297 | $117,947 | $397 |
| Rhopressa | 141 | $78,386 | $556 |
| Rocklatan | 137 | $53,183 | $388 |
| Alphagan P | 136 | $49,504 | $364 |
| Dorzolamide-Timolol | 929 | $44,212 | $48 |
| Simbrinza | 180 | $41,622 | $231 |
| Latanoprost | 1,512 | $40,548 | $27 |
| Travatan Z | 91 | $39,496 | $434 |
| Azopt | 85 | $38,322 | $451 |
| Ilevro | 85 | $35,475 | $417 |
| Travoprost | 131 | $34,378 | $262 |
| Zioptan | 50 | $23,184 | $464 |
| Restasis | 22 | $15,950 | $725 |
| Durezol | 75 | $15,498 | $207 |
| Vyzulta | 39 | $14,352 | $368 |
| Brimonidine | 198 | $13,439 | $68 |
| Prednisolone Acetate | 281 | $11,573 | $41 |
| Dorzolamide-Timolol | 48 | $8,942 | $186 |
| Timoptic Ocudose | 11 | $8,795 | $800 |
| Timolol Maleate | 460 | $8,463 | $18 |
| Loteprednol Etabonate | 46 | $8,232 | $179 |
| Dorzolamide | 159 | $5,366 | $34 |
| Ketorolac Tromethamine | 155 | $5,034 | $32 |
| Ofloxacin | 308 | $4,489 | $15 |
| Lotemax Sm | 17 | $3,587 | $211 |
| Atropine Sulfate | 79 | $3,310 | $42 |
| Betimol | 17 | $2,956 | $174 |
| Lotemax | 13 | $2,853 | $219 |
| Pilocarpine | 13 | $972 | $75 |
| Neomycin-Polymyxin-Dexameth | 51 | $851 | $17 |
| Polymyxin B Sul-Trimethoprim | 23 | $186 | $8 |
| Erythromycin | 12 | $160 | $13 |
2019: 35 drugs
| Lumigan | 401 | $179,318 | $447 |
| Travatan Z | 301 | $105,764 | $351 |
| Combigan | 270 | $104,107 | $386 |
| Rhopressa | 161 | $69,100 | $429 |
| Alphagan P | 150 | $47,212 | $315 |
| Simbrinza | 189 | $41,272 | $218 |
| Dorzolamide-Timolol | 683 | $36,699 | $54 |
| Azopt | 82 | $34,310 | $418 |
| Latanoprost | 1,223 | $30,440 | $25 |
| Ilevro | 84 | $29,270 | $348 |
| Zioptan | 72 | $22,233 | $309 |
| Durezol | 97 | $19,138 | $197 |
| Timoptic Ocudose | 19 | $15,211 | $801 |
| Lotemax | 56 | $14,052 | $251 |
| Prednisolone Acetate | 322 | $13,611 | $42 |
| Brimonidine | 136 | $12,863 | $95 |
| Restasis | 11 | $10,466 | $951 |
| Vyzulta | 25 | $9,884 | $395 |
| Dorzolamide | 207 | $8,469 | $41 |
| Ofloxacin | 369 | $7,961 | $22 |
| Timolol Maleate | 485 | $7,664 | $16 |
| Rocklatan | 22 | $7,580 | $345 |
| Cosopt Pf | 22 | $6,494 | $295 |
| Atropine Sulfate | 123 | $4,894 | $40 |
| Loteprednol Etabonate | 21 | $4,099 | $195 |
| Dorzolamide-Timolol | 21 | $3,867 | $184 |
| Pazeo | 12 | $2,724 | $227 |
| Betimol | 12 | $2,396 | $200 |
| Ketorolac Tromethamine | 64 | $1,730 | $27 |
| Pilocarpine | 22 | $1,647 | $75 |
| Neomycin-Polymyxin-Dexameth | 109 | $1,574 | $14 |
| Betaxolol | 11 | $768 | $70 |
| Cyclopentolate | 15 | $255 | $17 |
| Levobunolol | 23 | $240 | $10 |
| Polymyxin B Sul-Trimethoprim | 17 | $143 | $8 |
2018: 30 drugs
| Lumigan | 346 | $137,590 | $398 |
| Travatan Z | 289 | $97,538 | $338 |
| Combigan | 275 | $83,687 | $304 |
| Alphagan P | 138 | $38,058 | $276 |
| Azopt | 103 | $36,234 | $352 |
| Rhopressa | 81 | $29,415 | $363 |
| Simbrinza | 147 | $28,548 | $194 |
| Latanoprost | 1,033 | $22,349 | $22 |
| Lotemax | 80 | $21,705 | $271 |
| Timoptic Ocudose | 27 | $15,745 | $583 |
| Zioptan | 56 | $14,539 | $260 |
| Dorzolamide-Timolol | 480 | $12,212 | $25 |
| Prednisolone Acetate | 255 | $11,855 | $46 |
| Brimonidine | 107 | $11,158 | $104 |
| Vyzulta | 20 | $10,822 | $541 |
| Cosopt Pf | 38 | $7,597 | $200 |
| Timolol Maleate | 525 | $7,304 | $14 |
| Ilevro | 15 | $5,016 | $334 |
| Dorzolamide | 195 | $4,919 | $25 |
| Ofloxacin | 301 | $4,709 | $16 |
| Durezol | 24 | $4,506 | $188 |
| Atropine Sulfate | 76 | $2,188 | $29 |
| Pilocarpine | 25 | $1,990 | $80 |
| Neomycin-Polymyxin-Dexameth | 84 | $1,141 | $14 |
| Betaxolol | 20 | $1,098 | $55 |
| Azelastine | 12 | $880 | $73 |
| Doxycycline Hyclate | 20 | $872 | $44 |
| Ketorolac Tromethamine | 18 | $856 | $48 |
| Polymyxin B Sul-Trimethoprim | 12 | $109 | $9 |
| Levobunolol | 13 | $71 | $5 |
2017: 26 drugs
| Lumigan | 309 | $98,717 | $319 |
| Travatan Z | 239 | $73,827 | $309 |
| Combigan | 208 | $50,838 | $244 |
| Alphagan P | 108 | $24,854 | $230 |
| Simbrinza | 113 | $19,706 | $174 |
| Latanoprost | 872 | $19,111 | $22 |
| Lotemax | 72 | $18,484 | $257 |
| Prednisolone Acetate | 180 | $11,978 | $67 |
| Dorzolamide-Timolol | 485 | $11,490 | $24 |
| Azopt | 34 | $10,960 | $322 |
| Restasis | 12 | $10,746 | $896 |
| Zioptan | 33 | $10,559 | $320 |
| Timoptic Ocudose | 17 | $10,365 | $610 |
| Ilevro | 31 | $9,597 | $310 |
| Brimonidine | 108 | $8,147 | $75 |
| Durezol | 31 | $7,564 | $244 |
| Dorzolamide | 215 | $5,367 | $25 |
| Cosopt Pf | 20 | $5,357 | $268 |
| Timolol Maleate | 366 | $4,781 | $13 |
| Ofloxacin | 300 | $4,081 | $14 |
| Betaxolol | 23 | $1,528 | $66 |
| Pilocarpine | 18 | $1,465 | $81 |
| Atropine Sulfate | 33 | $1,259 | $38 |
| Fluorometholone | 11 | $1,236 | $112 |
| Neomycin-Polymyxin-Dexameth | 53 | $771 | $15 |
| Doxycycline Hyclate | 11 | $724 | $66 |
2016: 25 drugs
| Lumigan | 337 | $96,035 | $285 |
| Combigan | 244 | $46,941 | $192 |
| Travatan Z | 163 | $46,723 | $287 |
| Ilevro | 102 | $28,254 | $277 |
| Alphagan P | 104 | $22,247 | $214 |
| Simbrinza | 129 | $20,013 | $155 |
| Restasis | 18 | $15,056 | $836 |
| Latanoprost | 830 | $13,753 | $17 |
| Prednisolone Acetate | 201 | $13,651 | $68 |
| Lotemax | 54 | $11,488 | $213 |
| Azopt | 36 | $10,608 | $295 |
| Durezol | 41 | $10,417 | $254 |
| Dorzolamide-Timolol | 461 | $10,192 | $22 |
| Brimonidine | 109 | $6,095 | $56 |
| Timoptic Ocudose | 11 | $4,987 | $453 |
| Zioptan | 23 | $4,927 | $214 |
| Ofloxacin | 258 | $4,342 | $17 |
| Timolol Maleate | 346 | $3,303 | $10 |
| Dorzolamide | 165 | $3,289 | $20 |
| Fluorometholone | 37 | $2,900 | $78 |
| Neomycin-Polymyxin-Dexameth | 104 | $2,116 | $20 |
| Pilocarpine | 16 | $1,499 | $94 |
| Betaxolol | 20 | $1,157 | $58 |
| Atropine Sulfate | 31 | $1,129 | $36 |
| Acetazolamide | 11 | $456 | $41 |
2015: 23 drugs
| Lumigan | 185 | $47,706 | $258 |
| Combigan | 195 | $33,602 | $172 |
| Ilevro | 104 | $25,762 | $248 |
| Travatan Z | 118 | $24,602 | $208 |
| Alphagan P | 100 | $18,475 | $185 |
| Prednisolone Acetate | 202 | $15,186 | $75 |
| Lotemax | 63 | $13,457 | $214 |
| Simbrinza | 102 | $13,254 | $130 |
| Durezol | 63 | $12,936 | $205 |
| Azopt | 41 | $11,391 | $278 |
| Latanoprost | 511 | $7,512 | $15 |
| Restasis | 11 | $7,092 | $645 |
| Dorzolamide-Timolol | 274 | $6,533 | $24 |
| Brimonidine | 74 | $5,708 | $77 |
| Ofloxacin | 268 | $4,301 | $16 |
| Zioptan | 19 | $3,123 | $164 |
| Neomycin-Polymyxin-Dexameth | 123 | $2,126 | $17 |
| Timolol Maleate | 253 | $1,844 | $7 |
| Dorzolamide | 91 | $1,765 | $19 |
| Pilocarpine | 21 | $1,642 | $78 |
| Betaxolol | 20 | $1,370 | $69 |
| Atropine Sulfate | 30 | $803 | $27 |
| Acetazolamide | 13 | $729 | $56 |
2014: 22 drugs
| Lumigan | 104 | $24,007 | $231 |
| Combigan | 110 | $15,421 | $140 |
| Lotemax | 80 | $15,095 | $189 |
| Prednisolone Acetate | 173 | $12,483 | $72 |
| Alphagan P | 55 | $12,061 | $219 |
| Travatan Z | 46 | $8,461 | $184 |
| Durezol | 43 | $7,737 | $180 |
| Latanoprost | 249 | $4,834 | $19 |
| Azopt | 27 | $4,522 | $167 |
| Simbrinza | 31 | $3,473 | $112 |
| Dorzolamide-Timolol | 119 | $3,158 | $27 |
| Ofloxacin | 208 | $2,223 | $11 |
| Neomycin-Polymyxin-Dexameth | 96 | $1,642 | $17 |
| Dorzolamide | 56 | $1,632 | $29 |
| Timolol Maleate | 138 | $1,321 | $10 |
| Acetazolamide | 13 | $1,191 | $92 |
| Brimonidine | 15 | $1,052 | $70 |
| Pilocarpine | 12 | $925 | $77 |
| Betaxolol | 13 | $749 | $58 |
| Ketorolac Tromethamine | 19 | $661 | $35 |
| Atropine Sulfate | 32 | $540 | $17 |
| Hydrocodone-Acetaminophen | 19 | $113 | $6 |
2013: 11 drugs
| Lumigan | 14 | $2,480 | $177 |
| Lotemax | 11 | $2,178 | $198 |
| Durezol | 16 | $2,014 | $126 |
| Prednisolone Acetate | 38 | $1,153 | $30 |
| Latanoprost | 31 | $756 | $24 |
| Dorzolamide-Timolol | 23 | $677 | $29 |
| Neomycin-Polymyxin-Dexameth | 30 | $435 | $14 |
| Hydrocodone-Acetaminophen | 91 | $416 | $5 |
| Ofloxacin | 48 | $391 | $8 |
| Dorzolamide | 11 | $333 | $30 |
| Timolol Maleate | 14 | $195 | $14 |
Money from drug and device companies
$16,930 in 2025
| 2025 | 11 | 74 | $13,900 | $16,930 |
| 2024 | 12 | 72 | $14,000 | $18,608 |
| 2023 | 11 | 73 | $29,900 | $37,419 |
| 2022 | 11 | 60 | $30,230 | $32,186 |
| 2021 | 13 | 55 | $25,767 | $27,252 |
| 2020 | 10 | 66 | $40,055 | $42,386 |
| 2019 | 11 | 106 | $48,000 | $54,677 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Voyager Dslt | $6,140 | 29 payments
|
| New World Medical | Kahook Dual Blade | $4,882 | 8 payments
|
| Glaukos | Travoprost Intraocular Implant - Idose | $3,353 | 4 payments
|
| Alcon Research | None | $2,000 | 1 payment
|
| Abbvie | Durysta | $390 | 24 payments
|
| Nova Eye | None | $54 | 1 payment
|
See all 73 published payments
| Alcon Vision | Meals · 2025-12-18 | Clareon Panoptix Pro | $131 |
| Abbvie | Meals · 2025-12-10 | Durysta | $18 |
| Abbvie | Meals · 2025-12-09 | Lumigan | $8 |
| Alcon Vision | Meals · 2025-12-05 | Unity | $111 |
| Abbvie | Meals · 2025-11-20 | Durysta | $17 |
| Alcon Vision | Meals · 2025-11-20 | Rhopressa | $123 |
| Abbvie | Meals · 2025-11-08 | Durysta | $36 |
| Glaukos | Meals · 2025-11-08 | Idosetr | $130 |
| Alcon Research | Consulting · 2025-11-06 | None | $2,000 |
| Abbvie | Meals · 2025-11-03 | Lumigan | $3 |
| Abbvie | Meals · 2025-11-03 | Lumigan | $18 |
| New World Medical | Honoraria · 2025-10-21 | Kahook Dual Blade | $2,500 |
| Alcon Vision | Meals · 2025-10-18 | None | $192 |
| Abbvie | Meals · 2025-10-17 | Durysta | $56 |
| Alcon Vision | Meals · 2025-10-14 | Rocklatan | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-10-13 | Xdemvy | $17 |
| Abbvie | Meals · 2025-10-06 | Lumigan | $4 |
| Alcon Vision | Meals · 2025-09-30 | Rocklatan | $11 |
| Alcon Vision | Meals · 2025-09-30 | Rocklatan | $5 |
| Glaukos | Consulting · 2025-09-17 | None | $2,400 |
| Abbvie | Meals · 2025-09-04 | Lumigan | $8 |
| Harrow Eye | Meals · 2025-09-04 | None | $23 |
| Alcon Vision | Meals · 2025-09-02 | Rocklatan | $9 |
| Alcon Vision | Meals · 2025-09-02 | Rocklatan | $7 |
| Abbvie | Meals · 2025-08-28 | Lumigan | $6 |
| Abbvie | Meals · 2025-08-25 | Durysta | $31 |
| New World Medical | Consulting · 2025-08-20 | Kahook Dual Blade | $1,200 |
| Abbvie | Meals · 2025-08-13 | Durysta | $17 |
| Alcon Vision | Meals · 2025-07-29 | Clareon | $22 |
| New World Medical | Meals · 2025-07-28 | Kahook Dual Blade | $195 |
| Abbvie | Meals · 2025-07-21 | Lumigan | $4 |
| Sight Sciences | Meals · 2025-07-02 | Omni Surgical System | $17 |
| Thea Pharma | Meals · 2025-06-21 | Iyuzeh | $14 |
| Alcon Vision | Meals · 2025-06-17 | Rocklatan | $27 |
| Abbvie | Meals · 2025-06-09 | Lumigan | $5 |
| Glaukos | Meals · 2025-06-06 | None | $23 |
| Abbvie | Meals · 2025-05-22 | Lumigan | $4 |
| Alcon Vision | Consulting · 2025-05-22 | Voyager Dslt | $2,000 |
| Alcon Vision | Meals · 2025-05-20 | Rocklatan | $11 |
| Abbvie | Meals · 2025-05-19 | Xen Glaucoma Treatment System | $15 |
| Abbvie | Meals · 2025-05-15 | Durysta | $16 |
| Alcon Vision | Meals · 2025-05-15 | Hydrus Microstent | $130 |
| Alcon Vision | Meals · 2025-05-14 | Clareon | $23 |
| Abbvie | Meals · 2025-05-01 | Lumigan | $4 |
| Abbvie | Meals · 2025-04-29 | Xen Glaucoma Treatment System | $60 |
| Alcon Vision | Meals · 2025-04-22 | Rocklatan | $9 |
| Alcon Vision | Meals · 2025-04-22 | Rocklatan | $10 |
| Alcon Vision | Meals · 2025-04-22 | Rocklatan | $6 |
| Abbvie | Meals · 2025-04-18 | Lumigan | $8 |
| Abbvie | Meals · 2025-04-08 | Durysta | $23 |
| Alcon Vision | Meals · 2025-04-04 | Rocklatan | $10 |
| Nova Eye | Meals · 2025-04-04 | None | $54 |
| Alcon Vision | Meals · 2025-04-03 | Clareon | $20 |
| Tarsus Pharmaceuticals | Meals · 2025-03-21 | Xdemvy | $19 |
| Alcon Vision | Meals · 2025-03-19 | Clareon | $22 |
| Abbvie | Meals · 2025-03-10 | Lumigan | $4 |
| Alcon Vision | Meals · 2025-03-06 | Rocklatan | $35 |
| Alcon Vision | Consulting · 2025-03-06 | Voyager Dslt | $1,500 |
| New World Medical | Meals · 2025-03-05 | Kahook Dual Blade | $214 |
| Alcon Vision | Meals · 2025-02-27 | None | $152 |
| Alcon Vision | Meals · 2025-02-25 | Hydrus Microstent | $16 |
| RxSight | Meals · 2025-02-24 | Rxsight Contact Lens | $19 |
| Alcon Vision | Consulting · 2025-02-06 | Voyager Dslt | $1,000 |
| Alcon Vision | Consulting · 2025-02-06 | Voyager Dslt | $500 |
| Glaukos | Consulting · 2025-02-05 | Travoprost Intraocular Implant - Idose | $800 |
| Abbvie | Meals · 2025-02-03 | Lumigan | $4 |
| New World Medical | Meals · 2025-01-29 | Kahook Dual Blade | $160 |
| New World Medical | Meals · 2025-01-27 | Kahook Dual Blade | $140 |
| New World Medical | Meals · 2025-01-24 | Kahook Dual Blade | $290 |
| Alcon Vision | Meals · 2025-01-17 | Hydrus Microstent | $25 |
| Abbvie | Meals · 2025-01-16 | Lumigan | $21 |
| Alcon Vision | Meals · 2025-01-16 | Hydrus Microstent | $25 |
| New World Medical | Meals · 2025-01-08 | Kahook Dual Blade | $184 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $18,608
| Glaukos | Idose | $8,238 | 12 payments
|
| Alcon Research | None | $4,250 | 2 payments
|
| Alcon Vision | Hydrus Microstent | $3,898 | 13 payments
|
| New World Medical | Kahook Dual Blade | $1,321 | 7 payments
|
| Abbvie | Lumigan | $566 | 23 payments
|
| RxSight | Rxsight Contact Lens | $162 | 6 payments
|
| Thea Pharma | Iyuzeh | $66 | 3 payments
|
| Bausch & Lomb Americas | Vyzulta | $33 | 2 payments
|
| Sight Sciences | Omni Surgical System | $24 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $21 | 1 payment
|
| Rayner Intraocular Lenses | Omidria | $15 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $14 | 1 payment
|
2023: $37,419
| Alcon Vision | Hydrus Microstent | $20,869 | 31 payments
|
| Alcon Research | None | $8,273 | 2 payments
|
| New World Medical | None | $5,751 | 12 payments
|
| Glaukos | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is | $1,539 | 6 payments
|
| AbbVie | Xen Glaucoma Treatment System | $731 | 10 payments
|
| Rayner Intraocular Lenses | Omidria | $93 | 4 payments
|
| Thea Pharma | Iyuzeh | $58 | 3 payments
|
| RxSight | Rxsight Contact Lens | $36 | 2 payments
|
| Carl Zeiss Meditec USA | Lumera 700 | $27 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $24 | 1 payment
|
| Biotissue Holdings | Prokera | $18 | 1 payment
|
2022: $32,186
| Iridex | None | $7,650 | 3 payments
|
| Alcon Vision | Rocklatan | $6,947 | 15 payments
|
| New World Medical | Kahook Dual Blade | $6,808 | 6 payments
|
| RxSight | Light Adjustable Lens (Lal) and Light Delivery Device (Ldd) | $4,137 | 3 payments
|
| Allergan | Durysta | $2,614 | 6 payments
|
| Glaukos | Istent Inject W | $2,248 | 6 payments
|
| Abbvie | Xen Glaucoma Treatment System | $1,690 | 16 payments
|
| Novartis Pharmaceuticals | Xiidra | $44 | 2 payments
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $20 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $14 | 1 payment
|
| BioTissue Holdings | Prokera | $14 | 1 payment
|
2021: $27,252
| Aerie Pharmaceuticals | Rocklatan | $13,487 | 10 payments
|
| Iridex | None | $6,000 | 3 payments
|
| Glaukos | Istent Inject W | $2,595 | 4 payments
|
| Allergan | Durysta | $2,461 | 17 payments
|
| New World Medical | Ahmed Glaucoma Valve | $2,064 | 6 payments
|
| Ivantis | Hydrus Microstent | $353 | 5 payments
|
| Alcon Vision | Acrysof Iq Panoptix | $130 | 3 payments
|
| Ocular Therapeutix | Dextenza | $50 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $42 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $20 | 1 payment
|
| Tissuetech | Prokera | $17 | 1 payment
|
| Omeros | Omidria | $16 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $14 | 1 payment
|
2020: $42,386
| Allergan | Durysta | $20,416 | 29 payments
|
| Aerie Pharmaceuticals | Rocklatan | $19,807 | 22 payments
|
| New World Medical | Ahmed Glaucoma Valve | $1,250 | 1 payment
|
| Ivantis | Hydrus | $552 | 3 payments
|
| Novartis Pharmaceuticals | Beovu | $130 | 2 payments
|
| Alcon Vision | Acrysof Iq Panoptix | $86 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $54 | 3 payments
|
| Glaukos | Photrexa | $49 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $20 | 1 payment
|
| Omeros | Omidria | $20 | 1 payment
|
2019: $54,677
| Allergan | Xen | $32,090 | 64 payments
|
| Aerie Pharmaceuticals | Rhopressa | $15,604 | 17 payments
|
| New World Medical | Ahmed Glaucoma Valve | $3,769 | 3 payments
|
| Glaukos | Istent Trabecular Micro-Bypass Stent System | $2,628 | 5 payments
|
| Bausch & Lomb a division of Bausch Health US | Envista | $260 | 10 payments
|
| Ivantis | Hydrus | $150 | 1 payment
|
| Alcon Vision | Panoptix | $75 | 1 payment
|
| Dompe US | Oxervate | $36 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $29 | 2 payments
|
| Novartis Pharmaceuticals | Durezol | $19 | 1 payment
|
| Iridex | None | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · Agn-193408 Sr in the Treatment of Open-Angle Glaucoma Or Ocular Hypertension · 2023 | Their institution | $51,949 |
| Alcon Research LLC · The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinical Trial · 2023 | Their institution | $39,462 |
| Glaukos Corporation · Prospective, Randomized Phase 3 Study Comparing Two Models of A Travoprost Intraocular Implant To Timolol Maleate Ophthalmic Solution, Usp, 0.5 · 2021 | Their institution | $36,338 |
| ABBVIE INC. · Agn-193408 Sr in the Treatment of Open-Angle Glaucoma Or Ocular Hypertension · 2024 | Their institution | $35,689 |
| Glaukos Corporation · A Prospective, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass System, Model Is3, in Subjects With Refractory Glaucoma · 2019 | Their institution | $34,829 |
| Allergan, Inc. · The Efficacy and Safety of Bimatoprost Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension · 2020 | Their institution | $27,799 |
| Alcon Research LLC · The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinical Trial · 2024 | Their institution | $26,556 |
| Glaukos Corporation · Multicenter, Randomized, Double-Masked Trial To Evaluate the Safety and Efficacy of Idose Tr (Travoprost Intraocular Implant) in Conjunction With the Placement of Istent Infinite Vs. Istent Infinite Alone in Subjects With Open-Angle Glaucoma Or Ocular Hypertension · 2024 | Their institution | $25,688 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2022 | Their institution | $24,040 |
| Alcon Research LLC · The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-Randomized, Multicenter, Single Arm Clinical Trial · 2025 | Their institution | $21,723 |
| Allergan Inc. · Xen-45 Gel Stent Versus Trabeculectomy in Glaucoma Gold-Standard Pathway Study Gps · 2019 | Their institution | $21,000 |
| Glaukos Corporation · Prospective, Randomized Phase 3 Study Comparing Two Models of A Travoprost Intraocular Implant To Timolol Maleate Ophthalmic Solution, Usp, 0.5% · 2020 | Their institution | $20,674 |
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2021 | Their institution | $19,992 |
| Ivantis, Inc · Confirm · 2021 | Their institution | $19,060 |
| Allergan Inc. · The Efficacy and Safety of Bimatoprost Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension · 2019 | Their institution | $17,843 |
| Ivantis, Inc · Hydrus(R) Microstent New Enrollment Post-Approval Study · 2020 | Their institution | $16,260 |
| RxSight Inc · Pmcs-002 · 2023 | Their institution | $16,000 |
| Glaukos Corporation · A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos Istent Trabecular Micro-Bypass Stent System in Conjunction With Cataract Surgery · 2019 | Their institution | $15,770 |
| GLAUKOS CORPORATION · 2022 | Their institution | $14,374 |
| Ivantis, Inc · Cs Summit · 2021 | Their institution | $14,367 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2023 | Their institution | $13,066 |
| Glaukos Corporation · A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos Istent Trabecular Micro-Bypass Stent System in Conjunction With Cataract Surgery · 2020 | Their institution | $12,975 |
| Glaukos Corporation · Prospective, Randomized Phase 3 Study Comparing Two Models of A Travoprost Intraocular Implant To Timolol Maleate Ophthalmic Solution, Usp, 0.5% · 2023 | Their institution | $12,338 |
| Glaukos Corporation · A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction With Cataract Surgery · 2019 | Their institution | $10,793 |
| ABBVIE INC. · Agn-193408 Sr in the Treatment of Open-Angle Glaucoma Or Ocular Hypertension · 2025 | Their institution | $8,216 |
| ABBVIE INC. · Agn-193408 Sr in the Treatment of Open-Angle Glaucoma Or Ocular Hypertension · 2022 | Their institution | $7,783 |
| Glaukos Corporation · Multicenter, Randomized, Double-Masked Trial To Evaluate the Safety and Efficacy of Idose Tr (Travoprost Intraocular Implant) in Conjunction With the Placement of Istent Infinite Vs. Istent Infinite Alone in Subjects With Open-Angle Glaucoma Or Ocular Hypertension · 2025 | Their institution | $7,735 |
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2022 | Their institution | $6,878 |
| ABBVIE INC. · 1698-302-007 Ph3 Extension Study (M21-489) · 2024 | Their institution | $5,895 |
| Allergan, Inc. · Xen-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (Gps) · 2020 | Their institution | $5,700 |
| ABBVIE INC. · Sr in the Treatment of Open-Angle Glaucoma Or Ocular Hypertension · 2025 | Their institution | $3,524 |
| Allergan Inc. · Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension · 2019 | Their institution | $3,220 |
| ABBVIE INC. · A Phase 1/2 Study To Evaluate the Safety and Efficacy of Agn-193408 Sr in Participants With Open-Angle Glaucoma Or Ocular Hypertension · 2024 | Their institution | $3,116 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2024 | Their institution | $3,060 |
| Glaukos Corporation · Prospective, Randomized Phase 3 Study Comparing Two Models of A Travoprost Intraocular Implant To Timolol Maleate Ophthalmic Solution, Usp, 0.5% · 2024 | Their institution | $2,836 |
| Glaukos Corporation · A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos Istent Trabecular Micro-Bypass Stent System in Conjunction With Cataract Surgery · 2021 | Their institution | $2,812 |
| Glaukos Corporation · A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction With Cataract Surgery · 2020 | Their institution | $2,675 |
| Glaukos Corporation · A Prospective, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass System, Model Is3, in Subjects With Refractory Glaucoma · 2020 | Their institution | $2,305 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2025 | Their institution | $2,013 |
| Glaukos Corporation · A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction With Cataract Surgery · 2021 | Their institution | $995 |
| ABBVIE INC. · A Phase 1/2 Study To Evaluate the Safety and Efficacy of Agn-193408 Sr in Participants With Open-Angle Glaucoma Or Ocular Hypertension · 2025 | Their institution | $837 |
| ABBVIE INC. · 1833-201-407 Ph2 Clinical Study (M21-467) · 2024 | Their institution | $837 |
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2020 | Their institution | $752 |
| Glaukos Corporation · Prospective, Randomized Phase 3 Study Comparing Two Models of A Travoprost Intraocular Implant To Timolol Maleate Ophthalmic Solution, Usp, 0.5% · 2020 | This clinician | $421 |
| Glaukos Corporation · Multicenter Randomized Double-Masked Trial To Evaluate the Safety and Efficacy of Idose Tr (Travoprost Intraocular Implant) in Conjunction With the Placement of Istent Infinite Vs. Istent Infinite Alone in Subjects With Open-Angle Glaucoma Or Ocular Hypertension · 2023 | Their institution | $166 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1740433945
- Licence
- CA A124655California A124655: Current · expires 2028-04-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X)
- Mailing address
- 1515 Response Rd, Sacramento, CA, 95815
- NPI first listed
- 2008-10-31
- NPI last updated
- 2022-07-13
- NPI record certified
- 2022-07-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2295 Fieldstone Dr Ste 140, Lincoln, CA, 95648